Caribou Biosciences, Inc. (CRBU) intrinsic value & 10-year financials
Caribou Biosciences, Inc. (CRBU) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 11.6% a year to $11.2M, with an average return on invested capital of 3.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.47
- Market cap
- $43.9M
- Revenue (FY2025)
- $11.2M
- Revenue growth (8-yr CAGR)
- 11.6%
- ROIC (10-yr avg)
- 3.8%
- Free cash flow (FY2025)
- -$112.4M
CRBU 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $11.2M | -$148.1M | -$1.59 | -$112.4M | -1329.4% | -74.4% |
| FY2024 | $10.0M | -$149.1M | -$1.65 | -$143.1M | -1667.2% | -55.1% |
| FY2023 | $34.5M | -$102.1M | -$1.38 | -$104.9M | -336.6% | -37.9% |
| FY2022 | $13.9M | -$99.4M | -$1.64 | -$97.4M | -768.2% | -51.1% |
| FY2021 | $9.6M | -$66.9M | -$1.05 | -$34.6M | -697.8% | -45.4% |
| FY2020 | $12.4M | -$34.3M | — | -$33.5M | -292.2% | 429.5% |
| FY2019 | $5.8M | -$23.4M | — | -$32.9M | -592.7% | -138.8% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Caribou Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Caribou Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -56.9% ROIC.
Caribou Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Caribou Biosciences, Inc. is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-33.61 per share.